YSYan Su

Yan Su

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan Su has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Wen Zhao

    Medical Oncology Department, Pediatric Oncology Center; National Key Clinical Discipline of Pediatric Oncology, Laboratory for Clinical Medicine, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    10 shared publications
  • Chao Duan

    Medical Oncology Department, Pediatric Oncology Center; National Key Clinical Discipline of Pediatric Oncology, Laboratory for Clinical Medicine, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    8 shared publications
  • Mei Jin

    Medical Oncology Department, Pediatric Oncology Center; National Key Clinical Discipline of Pediatric Oncology, Laboratory for Clinical Medicine, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    6 shared publications
  • Peiyi Yang

    Medical Oncology Department, Pediatric Oncology Center; National Key Clinical Discipline of Pediatric Oncology, Laboratory for Clinical Medicine, Capital Medical University, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    5 shared publications
  • Tong Yu

    Imaging Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    5 shared publications
  • Xiaoli Ma

    Medical Oncology Department, Pediatric Oncology Center; Laboratory for Clinical Medicine, Capital Medical University; Beijing Key Laboratory of Pediatric Hematology Oncology; Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China

    5 shared publications

Latest Publications

  • Open Access

    Mosaic DICER1 RNase IIIb hotspot mutation with multiple tumors: case report and literature review

    by Peiyi Yang, Mei Jin, Wen Zhao, Chao Duan, Jie Yu, Yanchao Qu, Libing Fu, Tong Yu, Xiaoman Wang, Ruolan Guo, et al.

    We present a case of a 6-month-old boy who was diagnosed with Peutz–Jeghers polyps, intestine fusiform mesenchymal tumor, Wilms tumor, and Ir type pleuropulmonary blastoma (PPB) successively, with mosaic DICER1 RNase IIIb hotspot mutation: c.5113G>A p.E1705K. The patient underwent surgeries to resect the intestine polyps, intestine tumor, Wilms tumor, nephroblastomatosis, and PPB, combined with chemotherapy aimed at Wilms tumor and PPB. Diseases were stable at follow-up 27 months since the initial diagnosis.

  • Open Access

    Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China

    by Wen Zhao, Peiyi Yang, Jing Qin, Cheng Huang, Hongjun Fan, Mei Jin, Chao Duan, Ying Wu, Xisi Wang, Chunying Cui, et al.

    Background: Real-world evidence on dinutuximab beta for high-risk neuroblastoma (NB) in the Chinese pediatric patients remains limited. This study evaluated clinical efficacy and safety of dinutuximab beta as first-line maintenance therapy in a real-world setting. Methods: We retrospectively analyzed pediatric patients newly diagnosed with high-risk NB who after induction and consolidation therapy, received dinutuximab beta combined with granulocyte-macrophage colony-stimulating factor and isotretinoin, with or without chemotherapy. The primary outcome was objective response rate (ORR); secondary outcomes included 1- and 2-year event-free survival (EFS) and overall survival (OS) rates, and safety. Results: Twenty-eight patients were included, with a median age of 56 months (range 27-113) at the initiation of dinutuximab beta. Prior to immunotherapy, 14 patients had achieved complete response (CR) and 14 partial response (PR). Among those with CR, the CR maintenance rate was 78.6% (11/14). In patients with PR, the ORR at the end of treatment (EOT) was 64.3% (9/14). Stratified by treatment modality, PR patients receiving dinutuximab beta with chemotherapy had a higher ORR than those treated with dinutuximab beta alone at EOT [70.0% (7/10) vs. 50.0% (2/4)]. Regarding autologous stem cell transplantation (ASCT) status, all 3 patients who underwent ASCT achieved CR at EOT (ORR: 100%), whereas the ORR among patients without ASCT was 54.5% (6/11). The overall 1-year and 2-year EFS rates were 88.2% [95% confidence interval (CI), 67.4–96.1%)] and 72.4% (95% CI, 41.4–88.8%), respectively; 1-year and 2-year OS rates were both 95.8% (95% CI, 73.9–99.4%). Adverse events (AEs) were common but mostly mild to moderate in severity. Grade 3 or higher AEs occurred predominantly in patients who received combination chemotherapy, including fever, neutropenia, and thrombocytopenia. Pain was effectively managed with most patients requiring only minimal oral morphine (0.01–0.05 mg/kg/d) during cycles 3–5. Conclusion: Dinutuximab beta shows favorable efficacy for pediatric patients with high-risk NB. Patients treated with prior ASCT or combined with chemotherapy showed trends toward improved response rates and survival outcomes, although optimal treatment regimens required further investigation. AEs are generally manageable, and the use of standardized pain assessment combined with multimodal analgesia has enabled a substantial reduction in morphine exposure.


  • Open Access

    Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN

    by Zhixia Yue, Lan Li, Shuguang Liu, Chao Gao, Sidou He, Tianlin Xue, Wen Zhao, Chunying Cui, Chao Duan, Yan Su

    Current risk stratification for neuroblastoma (NB) relies on limited markers like MYCN amplification. Coilin, a key Cajal body component, regulates cellular processes. This study investigates whether coilin expression in bone marrow (BM) serves as a predictive biomarker for NB progression and elucidate its function in this disease. The functions and molecular mechanisms of coilin were investigated by employing cell lines and animal models. Coilin mRNA levels in patient samples were measured by RT-PCR, and their relationships with clinicobiological characteristics and outcomes were analyzed. Cisplatin induced dramatic changes of coilin distribution and expression. Databases showed that high expression of coilin exerted predictive values for poor outcome in NB. Coilin promoted proliferation in vitro and in vivo. Knockdown of coilin expression inhibited cell migration and invasion, promoted apoptosis and increased the Cisplatin drug sensitivity. Moreover, coilin activates p53/p21 signaling pathway and was a direct target of MYCN. Analysis of BM samples demonstrated that high expression of coilin was obviously associated with adverse clinical biological features. Importantly, the levels of coilin at diagnosis were markedly higher than those at the time before maintenance treatment in the exact paired patients. Survival analysis presented that high coilin expression in BM is associated with poor prognosis. A novel and accessible coilin-targeted liquid biopsy method was developed, capable of detecting minimal residual disease (MRD) in early-stage NB and predicting disease progression and recurrence. Coilin was transcriptionally regulated by MYCN, offering potential avenues for the development of novel drugs or intervention strategies.


  • Open Access

    Ewing’s sarcoma family of tumors in adolescents in Beijing 2010–2019: a multicenter retrospective cohort study

    by Wen Zhao, Zhen Huang, Weiling Zhang, Qing Sun, Tian Zhi, Yao Xie, Qi Zeng, Lejian He, Weihong Zhao, Dongsheng Huang, et al.

    Background: Ewing’s sarcoma family of tumors (ESFTs) comprises a group of aggressive malignancies predominantly affecting children and adolescents. This study aimed to evaluate the clinical characteristics, treatment outcomes, and prognostic factors in adolescent patients with ESFTs. Methods: A multicenter, retrospective cohort study was conducted on adolescents (aged 10–18 years) diagnosed with ESFTs between January 2010 and December 2019 across four major pediatric hospitals in Beijing, China. Results: A total of 79 patients were included. Primary tumors originated in bone in 75.9% of cases and in soft tissue in 24.1%, with metastases present at diagnosis in 31.6% of patients. The median tumor diameter was 5.8 cm for bone lesions and 8.0 cm for soft tissue lesions. Most patients (91.1%) received multimodal treatment. The 5-year overall survival (OS) and event-free survival rates were 64.5% and 59.0%, respectively. Univariate analysis identified several factors associated with poorer survival: tumor diameter exceeding 8 cm, trunk as the primary tumor site, absence of multimodal treatment, and initiation of local therapy more than 18 weeks after diagnosis. However, multivariate analysis revealed that metastatic disease at presentation was the only independent predictor of reduced OS. Conclusions: Metastasis is a prevalent and critical prognostic factor in adolescent ESFT patients. Multimodal treatment and timely initiation of local therapy may contribute to improved survival outcomes. These findings underscore the importance of early, comprehensive treatment strategies in managing ESFTs in adolescents.


  • Open Access

    Rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation as a paraneoplastic syndrome in neuroblastoma: case report

    by Shihan Zhang, Wen Zhao, Mei Jin, Huanmin Wang, Chunxiu Gong, Min Liu, Hong Qin, Chenghao Chen, Yan Su

    Background: Neuroblastoma, the most common extracranial solid tumour in childhood, is occasionally associated with paraneoplastic syndromes. These syndromes can occur before tumour diagnosis or recurrence. Notably, approximately 40% of patients with rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) have underlying neural crest tumours, such as ganglioneuromas or ganglioneuroblastomas. ROHHAD may also manifest as a paraneoplastic syndrome in neuroblastomas. Here, we describe three neuroblastoma cases with ROHHAD to help improve oncologists’ recognition of ROHHAD as a paraneoplastic entity. Case Description: The three neuroblastoma cases (two females, one male) were diagnosed at 102, 44, and 9 months of age, respectively. The histopathological subtypes included ganglioneuroblastomas (n=2) and a neuroblastoma (n=1). Rapid-onset obesity occurred at 95 months (7.9 years), 33 months (2.8 years), and 72 months (6 years) of age. All three children underwent resection of their primary tumour, with one receiving adjuvant chemotherapy. For the treatment of ROHHAD, case 1 received immunomodulatory therapy comprising glucocorticoids, intravenous immunoglobulin (IVIG), and rituximab; case 2 did not receive immunotherapy; and case 3 was treated with oral prednisone therapy. All cases demonstrated sustained survival at last follow-up. Conclusions: ROHHAD syndrome may manifest as a paraneoplastic phenomenon in neuroblastoma patients. Oncologists should suspect ROHHAD in children with neuroblastoma who develop rapid-onset obesity, even in the absence of classic features such as hypoventilation or hypothalamic endocrine dysregulation. Implementing a multidisciplinary collaborative approach to care will enable early recognition and intervention. This will critically impact patient prognosis by facilitating prompt tumour surveillance while significantly improving long-term survival rates.


  • Open Access

    Brain metastasis of pleuropulmonary blastoma: case reports

    by Sidou He, Wen Zhao, Chao Duan, Libing Fu, Tong Yu, Ming Ge, Zhikai Liu, Chunying Cui, Xiaoli Ma, Yan Su

    Background: Pleuropulmonary blastoma (PPB) is a rare and highly aggressive malignant tumor of the lung or pleura, primarily affecting children and closely associated with DICER1 gene mutations. Patients with type II and III PPB are prone to distant metastasis, with the central nervous system (CNS) being the most common site of metastasis, leading to a poor prognosis. Case Description: This article provides a detailed account of the clinical manifestations, diagnostic processes, treatment plans, and follow-up outcomes of three children diagnosed with PPB accompanied by brain metastasis. Through the collaborative diagnosis and treatment by a multidisciplinary team, all three patients are currently in remission. As part of the diagnostic and treatment process, genetic testing was performed on two of the patients, revealing a pathogenic mutation in the DICER1 gene in one of them. Conclusions: Although the optimal treatment regimen for CNS metastasis in PPB remains unclear, combined treatment approaches offer new possibilities. In particular, brain computed tomography (CT) or magnetic resonance imaging (MRI) scans should be conducted every 3 months following the diagnosis of PPB to facilitate early detection of brain metastasis. Additionally, diagnosing PPB brain metastasis is challenging, and integrating patient history with genetic testing results plays a crucial role in distinguishing between primary intracranial tumors and PPB intracranial metastasis.


  • Open Access

    High-Density Lipoprotein Biomimetic Inorganic–Organic Composite Nanosystem for Atherosclerosis Therapy

    by Yunpeng Zhang, Danni Liu, Yaoqi Wang, Qi Sun, Dong Mei, Xiaoling Wang, Yan Su, Siyu Liu, Chunying Cui, Shuang Zhang

    Atherosclerosis (AS) is an important causative agent of cardiovascular diseases, and the occurrence and development of AS is accompanied by oxidative stress, so antioxidant therapy has become one of the strategies for the treatment of AS. This study aimed to design and construct an apolipoprotein ApoA1-modified inorganic–organic composite nanosystem for AS therapy, in which ApoA1 was modified onto carboxylated CeO2/Mn3O4 by covalent bonding, resulting in an inorganic–organic nanocomplex with a structure similar to that of high-density lipoprotein. The nanocomplex could effectively deliver the antioxidant nanoparticles to the AS plaque through the specific recognition between ApoA1 and the macrophage at the AS lesion site. For one thing, the nanocomplex could alleviate the oxidative stress environment of the AS site through the highly efficient antioxidant effect of CeO2/Mn3O4, which played a therapeutic role in the treatment of AS. For another, it could effectively eliminate the formed lipid plaques and maximally alleviate and treat AS by utilizing the cholesterol efflux effect of ApoA1.


  • Open Access

    Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study

    by Wen Zhao, Yuchen Zhou, Xisi Wang, Peiyi Yang, Cheng Huang, Xiaoli Ma, Yan Su, Rui Zhang

    The chemotherapy regimens recommended for both rhabdomyosarcoma (RMS) and Ewing sarcoma (ES) patients are myelosuppressive and can reduce the absolute neutrophil count (ANC) and subsequently increase the risk of febrile neutropenia (FN). However, only a few studies have focused on the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) drugs in pediatric and adolescent patients with RMS and ES. Our objective was to investigate the efficacy and safety of mecapegfilgrastim, a biosimilar of pegfilgrastim, in prophylaxis of FN for pediatric and adolescent patients with RMS or ES. In this single-arm, single-center, prospective study, pediatric and adolescent patients with RMS or ES were enrolled to receive either VAC (vincristine, cyclophosphamide, dactinomycin) regimen or VDC (vincristine, cyclophosphamide, doxorubicin) regimen in a 3-week cycle, followed by treatment with mecapegfilgrastim (100 μg/kg, maximum 6 mg) given at 24 h after completing chemotherapy. The primary endpoint was the incidence rate of FN. Secondary endpoints included the incidence rate of grade 4 neutropenia, duration of ANC ≤ 0.5 × 109/L, incidence rate of chemotherapy delay or reduction, use of antibiotics, and safety profile. In total, 2 of the 30 (6.7%, 95% CI: 0.82–22.07) patients experienced FN after the first cycle of chemotherapy. Eight (26.7%, 95% CI: 12.28–45.89) patients experienced grade 4 neutropenia after receiving prophylactic mecapegfilgrastim. Eight patients experienced ANC ≤ 0.5 × 109/L with a median duration of 4.5 days; among them, 6 patients reached the lowest point of their ANC level on day 7, and 5 of them recovered by day 10. No dose reductions, delays, or discontinuation of chemotherapy was reported. Twenty-one (70.0%) patients received antibiotics during the treatment period. No patient experienced FN in the 0–5 years and the 13–18 years groups, and 2 patients experienced FN in the 6–12 years group. Two patients, 6 patients, and no patient experienced grade 4 neutropenia in the 0–5 years, 6–12 years, and 13–18 years groups, respectively. Mecapegfilgrastim showed acceptable efficacy and safety profile in pediatric and adolescent patients with RMS or ES. Further randomized studies with large sample size are warranted. This clinical trial was registered at Chictr.org.cn (No.ChiCTR1900022249). Registered on March 31, 2019.


  • Open Access

    Clinical outcomes and prognostic factors of parameningeal rhabdomyosarcoma in children and adolescents: results of two consecutive protocols

    by Chao Duan, Sidou He, Xiaoli Ma, Shengcai Wang, Mei Jin, Wen Zhao, Xisi Wang, Zhikai Liu, Tong Yu, Lejian He, et al.

    Background: Parameningeal rhabdomyosarcoma (PM-RMS) accounts for about 20% of all rhabdomyosarcoma (RMS) cases. At present, most research on PM-RMS has been conducted in Europe and the United States of America, and research in China has been very limited. This study sought to analyze the clinical outcomes and prognostic factors of PM-RMS in children and adolescents from two consecutive protocols at Beijing Children’s Hospital (BCH). Methods: A total of 80 patients aged up to 18 years with previously untreated PM-RMS who had received treatment under two consecutive protocols [i.e., either the BCH-RMS-2006 protocol or the Chinese Children Cancer Group (CCCG)-RMS-2016 protocol] were included in the statistical analysis. The Kaplan-Meier method was used for the survival analysis, and Cox regression was used for the univariate and multivariate analyses. Results: Of the 80 patients enrolled in the study, 69 (86.2%) had meningeal invasion (MI). Of these 69 MI patients, 18 (22.5%) had cranial nerve palsy (CNP), 64 (80.0%) had cranial base bone erosion (CBBE), 25 (31.3%) had intracranial extension (ICE), and 2 (2.5%) had positive cerebrospinal fluid (CSF) tumor cells. The median follow-up time was 20.5 months (range, 5–100 months). The 5-year overall survival (OS) and progression-free survival (PFS) rates for the entire cohort were 51.7% and 45.6%, respectively. The 5-year OS rates of the patients who received the BCH-RMS-2006 protocol (18/80, 22.5%) and the CCCG-RMS-2016 protocol (62/80, 77.5%) were 33.3% and 57.0%, respectively (PConclusions: Of the patients examined in this study, those with PM-RMS with CBBE accompanied by ICE had the worst prognosis. The patients with MI benefited from intensive chemotherapy combined with radiation therapy, but the effect of surgery was very limited.


  • Open Access

    Impact of the COVID-19 pandemic on the demographic and disease burden of pediatric malignant solid tumors in China: a single-center, cross-sectional study

    by Chiyi Jiang, Yeran Yang, Wenfa Yang, Xiaoli Ma, Ping Chu, Chao Duan, Xinyu Wang, Binglin Jian, Wen Zhao, Sidou He, et al.

    Background: With the development of the novel coronavirus disease 2019 (COVID-19), China implemented measures in an attempt to control the infection rate. We conducted a single-center, cross-sectional study to ascertain the impact of the COVID-19 pandemic on the equitable availability of medical resources for children diagnosed with malignant solid tumors in China. Methods: Data on the demographics, clinical characteristics, and medical expenses of 876 patients diagnosed with neuroblastoma, rhabdomyosarcoma (RMS), Wilms tumor, hepatoblastoma (HB), Ewing sarcoma (ES), and central nervous system (CNS) tumors from 2019 to 2021, during the COVID-19 pandemic, were retrospectively collected from the National Center for Children’s Health. The Pearson χ2 test and Mann-Whitney test were performed to analyze the differences among variables. Results: Except for the regional origin of children with tumors during the epidemic, no significant differences were found in the demographic or clinical characteristics of patients at initial diagnosis. The number of patients from northern China and northeastern China who attended Beijing Children’s Hospital (BCH) increased after the outbreak of COVID-19 (P=0.001). There was no significant alteration observed in the frequency of hospitalizations per individual per annum (P=0.641) or the mean expense incurred per individual per hospitalization (P=0.361). In addition, the medical insurance coverage rate of real-time settlement increased year by year. Conclusions: After the COVID-19 outbreak, the origin of patients with solid tumor who visited BCH was concentrated in the northern region of China. COVID-19 had no impact on the other demographic factors, clinical characteristics, or economic burden of patients with pediatric malignant solid tumors.